| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 14 Feb 2026 | 4 Feb 2026 |
| Quarterly Results Omkar Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Unaudited Standalone Financial Results Of The Company For The Quarter And Nine months Ended on 31.12.2025 Dear Sir, Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please note that the Board in their meeting held on 14th February, 2026 has considered and approved the following business: 1. The Board approved the Unaudited Financial Results of the Company along with the Limited Review Report for the quarter and Nine Months ended on 31st December, 2025. The Board took note of the completion of the tenure of Mr. Janak Raj Sharma (DIN: 07420418) as an Independent Director of the Company. Mr. Janak Raj Sharma has completed two consecutive terms of five (5) years each and accordingly ceased to be an Independent Director of the Company upon the close of business hours on 12th February, 2026. (As Per BSE Announcement Dated on:14.02.2026) | ||
| Board Meeting | 14 Nov 2025 | 6 Nov 2025 |
| Omkar Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve Omkar Pharmachem Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve Unaudited Standalone Financial Results Of The Company For The Quarter & Half Yearly Ended September 30 2025. Dear Sir, Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please note that the Board in their meeting held on 14th November, 2025 has considered and approved the following business: 1. Unaudited Financial Results of the Company for the quarter and half yearly ended on 30th September, 2025. Unaudited Financial Results for the Quarter and Half yearly ended on 30th September, 2025 (As Per BSE Announcement Dated on 14.11.2025) | ||
| Board Meeting | 27 Aug 2025 | 27 Aug 2025 |
| Outcome of the Board Meeting held on 27th August, 2025 | ||
| Board Meeting | 13 Aug 2025 | 5 Aug 2025 |
| Omkar Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve Unaudited Standalone Financial Results Of The Company For The Quarter Ended June 30 2025. Dear Sir, Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please note that the Board in their meeting held on 13th August, 2025 has considered and approved the following business: 1. Unaudited Financial Results of the Company for the quarter ended on 30th June, 2025 (As Per BSE Announcement Dated on: 13.08.2025) | ||
| Board Meeting | 28 Jun 2025 | 28 Jun 2025 |
| Dear Sir, Please find enclosed the Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 w.r.t change in management of the Company. | ||
| Board Meeting | 29 May 2025 | 21 May 2025 |
| Audited Results Outcome of the board meeting held on 29th May 2025 for approval of Audited financial statements for Quarter and year ended on March 2025 (As Per BSE Announcement Dated on: 29/05/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
